fwiw I was never certain we'd beat CAP's pul result, but I felt it a likely probability, and with better safety profile I was like many here, over exposed to this ship wreck. I never envisaged an outcome under or inline with placebo, and for that reason I'm sure we've been mislead. You could argue the result we had was a possible outcome - ATL1102 doing nothing, even though it addressed CD49d and that was a biomarker from peer reviewed scientific papers, which Voit no doubt felt would result in some fruition, otherwise I doubt he'd have any interest in being involved. I believed our result would be 30% placebo effect, minus the +7 outlier which brought us to a +.11 outcome. That was my conservative estimate which I think I posted somewhere. To have our result equal to placebo / or slightly worse as it was just screams foul play to me and whilst no one's going to jail over this, they should.
- Forums
- ASX - By Stock
- Ann: Change of Interest of Substantial Holder from PVL
PER
percheron therapeutics limited
Add to My Watchlist
0.00%
!
1.0¢

fwiw I was never certain we'd beat CAP's pul result, but I felt...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.87M |
Open | High | Low | Value | Volume |
1.0¢ | 1.0¢ | 1.0¢ | $727 | 72.68K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 2840316 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 3323423 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 2840316 | 0.010 |
6 | 5659202 | 0.009 |
4 | 1260267 | 0.008 |
3 | 1642854 | 0.007 |
2 | 3200000 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 3323423 | 6 |
0.012 | 1139598 | 3 |
0.013 | 1000000 | 1 |
0.014 | 2072000 | 4 |
0.015 | 1500000 | 1 |
Last trade - 12.00pm 20/06/2025 (20 minute delay) ? |
Featured News
PER (ASX) Chart |